Who
Cintia Piccina
U.S. CCO & Country Gen Manager
Company insider
Files Form 4 as: U.S. CCO & Country Gen Manager, Autolus Therapeutics; Chief Commercial Officer, Adaptimmune Therapeutics; Chief Commercial Officer, Kalaris Therapeutics.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $121K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 31 Jan 2022
- Last trade
- 2 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 3 Sep 2026 | AUTL Autolus TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K6,713 at $2.34 | filing |
| 2 Sep 2026filed 3 Sep 2026 | AUTL Autolus TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K6,713 at $2.34 | filing |
| 1 Sep 2026filed 3 Sep 2026 | AUTL Autolus TherapeuticsBiotechnology | SEC FORM 4 Code M | $47K20,000 at $2.35 | filing |
| 1 Sep 2026filed 3 Sep 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | AUTL Autolus TherapeuticsBiotechnology | SEC FORM 4 Code M | $47K20,000 at $2.35 | filing |
| 20 Feb 2025filed 20 Feb 2025 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —1,612,032 at $0.00 | filing |
| 20 Feb 2025filed 20 Feb 2025 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —1,074,696 at $0.00 | filing |
| 15 Jan 2025filed 15 Jan 2025 | Adaptimmune Therapeutics | SEC FORM 4 Sold | $7,40512,991 at $0.57 | filing |
| 18 Jun 2024filed 18 Jun 2024 | Adaptimmune Therapeutics | SEC FORM 4 Sold | $23K24,531 at $0.93 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —5,088,864 at $0.00 | filing |
| 18 Mar 2024filed 18 Mar 2024 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —1,130,832 at $0.00 | filing |
| 3 Jul 2023filed 5 Jul 2023 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —273,000 at $0.00 | filing |
| 3 Jul 2023filed 5 Jul 2023 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Code A | —147,000 at $0.00 | filing |
| 31 Jan 2023filed 31 Jan 2023 | Adaptimmune Therapeutics | SEC FORM 4 Sold | $22K11,890 at $1.87 | filing |
| 17 Jan 2023filed 17 Jan 2023 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —1,407,072 at $0.00 | filing |
| 17 Jan 2023filed 17 Jan 2023 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —314,256 at $0.00 | filing |
| 17 Jan 2023filed 17 Jan 2023 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —181,560 at $0.00 | filing |
| 1 Aug 2022filed 1 Aug 2022 | Adaptimmune Therapeutics | SEC FORM 4 Sold | $37K21,040 at $1.77 | filing |
| 31 Jan 2022filed 31 Jan 2022 | Adaptimmune Therapeuticsoption or derivative | SEC FORM 4 Code A | —3,376,992 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.